Grant to Schering. (a) 3DP hereby grants to Schering an exclusive, worldwide, sublicensable license under the 3DP Technology to research, develop, make, have made, use, sell and import for sale Licensed Compounds and Licensed Products in the Field. A list of the 3DP Patents identified as of the Effective Date is attached hereto as Schedule A. Such list shall be modified from time to time to reflect any changes to the 3DP Patents acquired by or coming under the Control of 3DP or its Affiliates during the term of this Agreement or within a period of six (6) months thereafter. (b) 3DP also hereby grants to Schering a nonexclusive, worldwide, sublicensable license under Non-uPA Inhibitor Patents to carry out research and development in respect of uPA Inhibitor Compounds during the Research Program and to use any results of such research and development for the development, manufacture or commercialization of Licensed Compounds and Licensed Products. (c) 3DP also hereby grants to Schering a nonexclusive, worldwide, sublicensable license under Improvements that are Controlled by 3DP during the term of this Agreement to research, develop, make, have made, use, sell and import for sale Licensed Products in the Field. (d) 3DP agrees not to develop or commercialize outside of the Field any Licensed Compound or Licensed Product that is being developed or marketed by Schering without the prior written approval of Schering, such approval not to be unreasonably withheld by Schering.
Appears in 2 contracts
Sources: License and Research Agreement (3 Dimensional Pharmaceuticals Inc), License and Research Agreement (3 Dimensional Pharmaceuticals Inc)